| Trial ID: | L4735 |
| Source ID: | NCT03241303
|
| Associated Drug: |
Acarbose
|
| Title: |
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
|
| Acronym: |
AlfaEx
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Glucose Metabolism Disorders
|
| Interventions: |
DRUG: Acarbose|DRUG: Placebo Oral Tablet|DRUG: Exendin (9-39)|DRUG: Placebo Saline
|
| Outcome Measures: |
Primary: Plasma glucose, The primary outcome is the difference between the effect of increased carbohydrate content in the distal part of the small intestine (obtained by inhibiting alpha-glucosidase with acarbose) on postprandial glucose tolerance (as assessed by area under curve (AUC) for plasma glucose during a standardised liquid mixed meal test) with and without blockade of GLP-1 signalling by exendin(9-39)., 240 min |
|
| Sponsor/Collaborators: |
Sponsor: University Hospital, Gentofte, Copenhagen | Collaborators: University of Copenhagen
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: TRIPLE (PARTICIPANT, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2017-08-01
|
| Completion Date: |
2018-01-01
|
| Results First Posted: |
|
| Last Update Posted: |
2020-03-26
|
| Locations: |
Center for Diabetesresearch, Hellerup, 2900, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT03241303
|
